Skip to main content
Open access
6 January 2011

Global Magnitude of Reported and Unreported Mesothelioma

Publication: Environmental Health Perspectives
Volume 119, Issue 4
Pages 514 - 518



Little is known about the global magnitude of mesothelioma. In particular, many developing countries, including some with extensive historical use of asbestos, do not report mesothelioma.


We estimated the global magnitude of mesothelioma accounting for reported and unreported cases.


For all countries with available data on mesothelioma frequency and asbestos use (n = 56), we calculated the 15-year cumulative number of mesotheliomas during 1994–2008 from data available for fewer years and assessed its relationship with levels of cumulative asbestos use during 1920–1970. We used this relationship to predict the number of unreported mesotheliomas in countries for which no information on mesothelioma is available but which have recorded asbestos use (n = 33).


Within the group of 56 countries with data on mesothelioma occurrence and asbestos use, the 15-year cumulative number of mesothelioma was approximately 174,300. There was a statistically significant positive linear relation between the log-transformed national cumulative mesothelioma numbers and the log-transformed cumulative asbestos use (adjusted R2 = 0.83, p < 0.0001). Extrapolated to the group of 33 countries without reported mesothelioma, a total of approximately 38,900 (95% confidence interval, 36,700–41,100) mesothelioma cases were estimated to have occurred in the 15-year period (1994–2008).


We estimate conservatively that, globally, one mesothelioma case has been overlooked for every four to five reported cases. Because our estimation is based on asbestos use until 1970, the many countries that increased asbestos use since then should anticipate a higher disease burden in the immediate decades ahead.
Malignant mesothelioma is a major public health concern, because this rare form of cancer—caused specifically by exposure to asbestos—is difficult to diagnose, has extremely poor prognosis, and is on the increase. Epidemics of mesothelioma have been reported nationally (Centers for Disease Control and Prevention 2009; Hodgson et al. 2005; Kjellstrom and Smartt 2000; Murayama et al. 2006) and regionally (Pelucchi et al. 2004; Peto et al. 1999), but available information is biased toward developed countries and regions (referred to hereafter as “countries”) with the resources to diagnose asbestos-related diseases (ARDs) and with known historical use of asbestos. At present, mesothelioma is grossly underreported in many developing countries (LaDou 2004; Takahashi and Karjalainen 2003), including some with known extensive use of asbestos.
Few attempts have been made to quantify the global incidence of mesothelioma. In a study of the total burden of occupational carcinogens, Driscoll et al. (2005) reported 43,000 mesothelioma deaths/year, based on an estimated proportion of exposed workers and levels of exposure, combined with absolute risk measures. This number, endorsed in a World Health Organization (WHO) document on the elimination of ARDs (WHO 2006a), is widely quoted to guide preventive activities. However, there has been no validation or reassessment of this 2005 estimate, possibly because the indices that were used are difficult to access and reproduce. Commonly available statistics should be used to address the shortage of information, which may also improve estimates of the disease burden.
In a previous study (Lin et al. 2007), we calculated the volume of asbestos consumed per head (per-capita asbestos use) from a report by the U.S. Geological Survey (USGS) (Virta 2006) and used this value as a surrogate for population exposure level. Our results indicated that rates of past asbestos use can predict recent death rates from four types of ARDs at national levels and explained the bulk of the variance (Lin et al. 2007). This relationship, albeit ecological, is likely to reflect a causal relationship. Other researchers have used this surrogate indicator to estimate or predict ARDs in different populations (Antao et al. 2009; Tse et al. 2010).
Information related to mesothelioma frequency is accumulating in relation to the growing number of national and regional registries (Leigh and Driscoll 2003; Marinaccio et al. 2007). In the present study, we estimated the magnitude of mesothelioma in the world accounting for both reported and unreported numbers by using a global database and extending our previous ecological model. We incorporated updated data from the widest possible sources of information, assuming that mortality reflects incidence for this fatal form of cancer. We employed cumulative indicators of asbestos use and number of mesothelioma cases, hypothesizing that recent national burden of mesothelioma is a consequence of historical cumulative use of asbestos. This relationship was then applied to countries that lack relevant health data.

Materials and Methods

We extracted all data on asbestos use from a report by the USGS (Virta 2006, 2009). We adopted the USGS definition of use (production plus import minus export), the data for which are available by country, in 10-year intervals from 1920 to 1970, in 5-year intervals from 1970 to 1995, and annually from 1995 to 2007. We treated a reported negative value of asbestos use (caused by storage, for example) as zero in this analysis. Using linear interpolation, cumulative asbestos use was calculated independently for two periods (1920–1970 and 1971–2007) to allow a sufficient lag time from the earlier period to that of mesothelioma observation (1994–2008). When necessary, we interpolated values for asbestos use for the calendar year lacking data.
The cumulative numbers of all types of mesothelioma [code C45; International Classification of Diseases, 10th Revision (ICD-10; WHO 2006a b] were obtained from the WHO Mortality Database (WHO 2010a) and tallied by country. Note that the WHO data comprise deaths registered in national civil registration systems, with underlying cause of death as coded by the relevant national authority (WHO 2010b). Data were extracted for countries with at least 3 years of data coded as C45 (ICD-10) or any of its subcategories. To maximize use of available data, we separately counted numbers recorded for malignant neoplasm of the pleura (code 163; International Classification of Diseases, 9th Revision (ICD-9; WHO 1977)]. To investigate countries that did not report data to the WHO, we used PubMed (National Center for Biotechnology Information 2010) and other sources to search for national frequency data published in English (Lee et al. 2010; Rüegger 2008). Data were prioritized for analysis in that order, and overlapping information was evaluated once only. For a number of countries, national counts of mesothelioma deaths were reported for intermittent years or did not span the entire period. For each country, the 15-year cumulative number was estimated by first calculating the annual mean of reported mesothelioma deaths from data available for fewer years, which was then multiplied by 15.
National population data were obtained from the WHO (2010a) and the U.S. Census Bureau (2010), and prioritized for use in that order.
Of the 89 analyzed countries, 12 warranted special treatment of asbestos use data because of political transition (e.g., disintegration, unification) or combined treatment with other countries/entities by the USGS. We used historical information in an unbiased manner to the extent possible to give continuity with data of countries existing today:
Data on asbestos use for the Soviet Union during 1920–1990 in the USGS database represented those of Russia and Kazakhstan combined (Virta 2006). We thus apportioned data recorded by the Soviet Union during 1920–1990 between Russia and Kazakhstan during 1920–1990 according to the ratio of use recorded by Russia and Kazakhstan during 1995–2007.
Data on asbestos use for West and East Germany during 1950–1985 were combined into one entity (i.e., Germany).
To account for the disintegration of Czechoslovakia in 1993 (United Nations 2010), data on asbestos use for Czechoslovakia during 1920–1990 were apportioned to the level of use during 1995–2007 between Czech Republic and Slovakia.
To account for the disintegration of Yugoslavia in 1991 (Duffield 2003), data on asbestos use for Yugoslavia during 1930–1990 were apportioned to the level of use during 1995–2007 among Bosnia and Herzegovina, Croatia, Serbia and Montenegro, the former Yugoslav Republic of Macedonia, and Slovenia (we treated Serbia and Montenegro as one entity).
Data on asbestos use for Belgium and Luxembourg were combined during 1930–2001 in the USGS database (Virta 2006). We apportioned these data to Belgium and Luxembourg according to the size of the respective populations during this period.
We compiled all data and performed descriptive statistics using Microsoft Excel (Microsoft Corporation, Redmond, WA, USA). We then conducted the regression analyses using SAS, version 9.1 (SAS Institute Inc., Cary, NC, USA). Because of the extremely wide dispersion of data for both asbestos and mesothelioma, data were log-transformed to construct the regression model: log10 (mortality) = B0 + [B1 × log10 (asbestos)], where B0 is the intercept and B1 is the coefficient. We applied PROC REG (SAS Institute Inc.) to obtain the parameters and their confidence limits, the adjusted R2, and p-values of the regression model. The size of the national populations was used as weights. To further obtain the confidence limits for the mean predicted value for each observation, we added the confidence limits for the mean option. This accounted for the variation due to estimating the parameters only. All the aforementioned processes were accomplished in one run of PROC REG.
After predicted values were obtained, based on the principle that if Yi ~ N(mi, si2) is the measurement for the ith cluster then Y = sum(Yi) ~ N[sum(mi), sum(si2)], the confidence limits for the sum of predicted values were calculated from the square root of the sum of the variance.
We used Sigmaplot (version 9.01; Systat Software Inc., San Jose, CA, USA) to draw the figure; the size of the bubbles is proportionate to the size of national populations of the year 2000. p-Values < 0.05 were deemed statistically significant in all analyses.


Globally, 89 countries had available information on frequency of mesothelioma and/or use of asbestos at the national level. These countries represented 82.6% of the global population in the year 2000. Of these countries, 56 had data for both mesothelioma frequency and asbestos use, and 33 had no mesothelioma frequency data but had data for asbestos use (Table 1).
Table 1 Baseline characteristics of the 89 analyzed countries/entities with available data for asbestos and/or mesothelioma.
Data categoryBoth asbestos and mesothelioma (n = 56)Asbestos only (n = 33)Total (n = 89)
Asbestos, recorded cumulative use (million metric tons)   
 During 1920–197051.214.265.4
 During 1971–200752.871.3124.1
Mesothelioma, reported cumulative mortality during 1994–2008 [No. of cases (no. of countries)]   
 ICD-10, code C4590,929 (50)0a (NA)NA
 ICD-9, code 163336 (4)0a (NA)NA
 Other data sourceb868 (2)0c (NA)NA
 Total92,133 (56)0 (33)NA
NA, not applicable.
No record in WHO mortality database.
Published articles in English identified via Pubmed or other source of national data (see References; Lee et al. 2010; Rüegger 2008).
Data cannot be identified.
The cumulative asbestos use during 1920–1970 was 51.2 million metric tons in the 56 countries having data on both mesothelioma frequency and asbestos use and 14.2 million metric tons in the 33 countries having data on asbestos use only, totaling 65.4 million metric tons in all 89 analyzed countries. This volume represented 100% of the global asbestos use during 1920–1970. By individual country, cumulative asbestos use was highly skewed, led by the United States, Russia, United Kingdom, Germany, and Japan, with volumes at 21.8, 8.4, 4.8, 4.1, and 3.2 million metric tons, respectively (Tables 2 and 3). The 56 countries with mesothelioma data reported a total of 92,133 deaths during 1994–2008 (336 of which were coded as ICD-9 163 by four countries) (Table 1).
Table 2 Reported and extrapolated 15-year cumulative mortality of mesothelioma during 1994–2008 in 56 countries/entities with data for mesothelioma mortality and use of asbestos.
 Country (abbreviation)Cumulative use of asbestos, (tons), 1920–1970Years with available data (n)Reported cumulative mortality (cases)Annual average of reported mortality (cases)Extrapolated 15-year cumulative mortality (cases)
1USA (USA)21,840,583717,0622,43736,561
2UK (GBR)4,829,517713,2391,89128,369
3Germany (DEU)4,144,82599,5691,06315,948
4Japan (JPN)3,210,3491411,21280112,013
5France (FRA)2,352,64686,60882612,390
6Canada (CAN)1,955,34751,6033214,809
7Italy (ITA)1,934,55833,7061,23518,530
8Australia (AUS)1,152,77683,7474687,026
9Belgium (BEL)1,110,21434671562,335
10Spain (ESP)701,56571,8402633,943
11Poland (POL)581,01310957961,436
12Brazil (BRA)577,33310955961,433
13Romania (ROU)550,7991058158872
14Slovakia (SVK)548,8741215413193
15Denmark (DNK)447,59013918711,059
16Mexico (MEX)422,645101,5131512,270
17Sweden (SWE)414,601111,3481231,838
18Netherlands (NLD)411,989135,1413955,932
19Austria (AUT)410,2497563801,206
20Argentina (ARG)338,870111,065971,452
21Finland (FIN)299,69513970751,119
22Switzerland (CHE)267,30245681422,130
23Republic of Korea (KOR)244,8021233928424
24Hungary (HUN)235,4421345135520
25South Africa (ZAF)203,566122,3221942,903
26Colombia (COL)196,345932336538
27Croatia (HRV)165,0111454739586
28Norway (NOR)158,0171264854810
29New Zealand (NZL)147,1977513731,099
30Cyprus (CYP)145,745421579
31Czech Republic (CZE)140,9201561141611
32Egypt (EGY)124,90847226
33Chile (CHL)103,780933137552
34Greece (GRC)a101,021151289128
35Malaysia (MYS)94,540620350
36Slovenia (SVN)94,1141227023338
37Venezuela (VEN)93,2101112411169
38Portugal (PRT)a90,605815219285
39Israel (ISR)78,1221026226393
40Taiwan (TWN)67,6701230025375
41Philippines (PHL)41,13255110153
42Luxembourg (LUX)38,749939465
43Serbia and Montenegro (SRB & MNE)34,2221231326391
44Uruguay (URY)33,914638695
45Bulgaria (BGR)33,5764359131
46Latvia (LVA)22,189131129129
47Costa Rica (CRI)11,718924340
48Iceland (ISL)6,4171228235
49Lithuania (LTU)5,3961113512184
50Guatemala (GTM)a3,75759227
51Panama (PAN)3,506714230
52Singapore (SGP)a3,1501347454
53Estonia (EST)2,3001245456
54Hong Kong (HKG)61677911169
55Netherlands Antilles (ANT)33545119
56Nicaragua (NIC)31644115
NA, not applicable.
Number of cases represents malignant neoplasm of the pleura (ICD-9 code 163).
Table 3 Predicted 15-year cumulative mortality of mesothelioma in 33 countries/entities with data only for use of asbestos.
 Country (abbreviation)Cumulative use of asbestos (tons), 1920–1970Predicted 15-year cumulative mortality (cases)95% CI
1Russia (RUS)8,443,92321,30815,026–30,218
2Kazakhstan (KAZ)2,301,2866,5005,006–8,440
3China (CHN)1,767,0865,1073,976–6,558
4India (IND)688,0152,1581,700–2,739
5Thailand (THA)152,378545400–741
6Zimbabwe (ZWE)122,595447323–617
7Algeria (DZA)90,005337238–477
8Swaziland (SWZ)87,868329232–468
9Iran (IRN)68,437262181–380
10Turkey (TUR)60,345234159–343
11Morocco (MAR)55,697217147–321
12Former Yugoslav Republic of Macedonia (MKD)48,829193129–288
13Lebanon (LBN)47,718189126–283
14Nigeria (NGA)34,44314091–216
15Peru (PER)a32,64513386–207
16Indonesia (IDN)29,92012379–193
17Democratic Republic of the Congo (COD)22,5799559–153
18Uganda (UGA)18,1397847–128
19Iraq (IRQ)16,2027042–117
20Zambia (ZMB)15,6076841–113
21Mozambique (MOZ)14,5666438–107
22Angola (AGO)14,3786337–106
23Jamaica (JAM)10,6984828–83
24Myanmar (MMR)10,6324828–83
25Tunisia (TUN)9,7244425–77
26Bolivia (BOL)8,9594123–72
27El Salvador (SLV)a6,5453117–56
28Kenya (KEN)3,153168–31
29Botswana (BWA)1,16363–14
30Senegal (SEN)79952–10
31Libya (LBY)54031–7
32Bosnia and Herzegovina (BIH)38721–6
33Madagascar (MDG)b16NANA
NA, not applicable.
Treated as lacking data on mesothelioma frequency because only 2 years of data were available in the WHO mortality database and no other information could be identified (see “Materials and Methods”).
Out of range of the regression model.
Table 2 shows the 15-year cumulative mortality of mesothelioma extrapolated from numbers reported for fewer years in the 56 countries with mesothelioma data, ranked in order of the cumulative asbestos use. The 15-year cumulative numbers are highly skewed but generally paralleled the level of cumulative asbestos use. Leading countries for the 15-year mesothelioma number are the United States (36,561 cases), the United Kingdom (28,369 cases), Italy (18,530 cases), Germany (15,948 cases), and France (12,390 cases) (Table 2). The total 15-year cumulative mortality was approximately 174,300 deaths.
Figure 1 shows scatterplots of national data for the group of 56 countries. There is a clear positive linear relation between the log-transformed values of the 15-year cumulative mortality of mesothelioma during 1994–2008 and the cumulative use of asbestos during 1920–1970. Cumulative asbestos use was a significant predictor of cumulative mesothelioma mortality, with an adjusted R2 value of 0.83 (p < 0.0001). Similar findings were obtained when data for the four countries reporting deaths coded to the ICD-9 were omitted, with an adjusted R2 value of 0.82 (p < 0.0001).
Figure 1 Relationship between 15-year cumulative mortality of mesothelioma (1994–2008) and cumulative use of asbestos (1920–1970) weighted by the size of national populations in 56 countries/entities with data for both mesothelioma and asbestos use. Asbestos use for 33 countries/entities without mesothelioma frequency data is indicated along the x-axis. The figure is based on the following regression model: log10(15-year cumulative mortality of mesothelioma) = β0 + β1 × log10(cumulative use of asbestos), where β0 = −1.998 (95% CI, −2.676 to −1.319) and β1 = 0.913 (95% CI, 0.800 to 1.026). Adjusted R2 = 0.827; p < 0.0001.
Table 3 shows the predicted 15-year cumulative mortality of mesothelioma in the group of 33 countries that lacked data on mesothelioma frequency; predictions were obtained from the value of cumulative asbestos use applied to the relationship obtained earlier. The range of cumulative asbestos use of the 33 countries, except for Madagascar, fell within the range reported by the 56 countries. Leading countries for the predicted 15-year mesothelioma number are Russia (21,300 cases), Kazakhstan (6,500 cases), China (5,100 cases), India (2,200 cases), and Thailand (500 cases). In total, an estimated 38,900 [95% confidence interval (CI), 36,700–41,100] mesothelioma cases possibly occurred but were unreported during 1994–2008.


It is unlikely that mesothelioma is absent in countries that have used asbestos but do not report mesothelioma frequency. There is increasing evidence that the extent of asbestos use can be used to predict subsequent incidence and mortality of ARDs at national levels (Antao et al. 2009; Lin et al. 2007; Nishikawa et al. 2008; Tse et al. 2010). This is not unexpected, as mesothelioma is almost exclusively attributable to past asbestos exposure. We thus postulated that national experiences would follow reasonably similar patterns where countries lacking mesothelioma data were probably “missing” the disease burden to an extent proportionate to the level of historical cumulative asbestos use. Based on available data of 56 countries, we observed that recent cumulative mortality of mesothelioma is closely related to historical cumulative use of asbestos. Further extrapolation of this relation to the 33 countries with no available data for mesothelioma suggested that one mesothelioma case is unreported for every four to five cases reported worldwide (38,900 unreported vs. 174,300 reported).
Accounting for the reported and unreported numbers, we estimated the global burden of mesothelioma to be 213,200 (15-year cumulative mortality during 1994–2008). This is equivalent to an annual average of approximately 14,200 cases, assuming a flat change rate, or approximately 25,000 cases in the year 2008 assuming a 10% annual increase rate (38,000 cases assuming a 20% annual increase rate). These estimates are larger than the estimated 10,000 mesothelioma deaths proposed by consensus for only the developed regions in the world (Tossavainen 1997) but smaller than the 43,000 mesothelioma deaths estimated for the world by Driscoll et al. (2005). Nevertheless, our values are reasonably close to those of earlier reports, despite the different methods used.
From the observed linear relation between log-transformed values of cumulative mesothelioma and asbestos, y = 10(0.913 * log x − 1.998), where y (cases) is the 15-year cumulative mesothelioma mortality for the period 1994–2008, and x (metric tons) is the cumulative asbestos use during 1920–1970. When values are back-transformed to their original units, there is a linear relation between variables x and y, each dispersed for a very wide range (i.e., to the power of 10). Further, the amount of asbestos use corresponding to one mesothelioma case (asbestos-to-mesothelioma ratio), or x/y, varies depending on the level of x. For example, the asbestos-to-mesothelioma ratio is 182–222 metric tons per case for cumulative use of 1,000–10,000 metric tons, and 271–331 metric tons per case for cumulative use of 100,000–1,000,000 metric tons [see Supplemental Material, Table 1 (doi:10.1289/ehp.1002845)]. The values recorded here for the asbestos-to-mesothelioma ratio should be distinguished from a ratio reported by Tossavainen (2004) and referenced widely (fixed value of 170 metric tons per case); that value was derived using data from 11 developed countries with looser definitions and time frame.
The present study is the first to provide a global estimate of missed mesothelioma cases accounting for the experience of countries with data. We directly compared national asbestos use and mesothelioma frequency using cumulative indicators (the denominator population would be common to all calculations of rates); this method had the advantage of directly estimating the disease burden and maximizing use of sparse data. Asbestos has an extremely long industrial life span, and populations are repeatedly exposed during production, maintenance, and abatement. Smoking is unrelated to mesothelioma and thus does not have to be accounted for as a confounder. These facts supported the assumption that cumulative asbestos use causes health effects that are reflected in the cumulative mesothelioma count in populations.
There are, however, obvious limitations in the methods in the present study, as well as potential sources of errors in the information applied. First and foremost, our findings are based on an ecological relation, and thus we do not know the extent to which the consumed amounts of asbestos reflected actual exposure levels of populations. Second, extrapolating from the collective experience of one group of countries to another may introduce bias, especially because the former group consisted of developed and developing countries, whereas the latter group consisted of predominantly developing countries. Third, we did not have information for consumed fiber types (e.g., amphiboles, chrysotile).
Whether and the extent to which the aforementioned limitations and possible errors collectively caused overestimation or underestimation merits further consideration. One potential source of overestimation (pertaining to the extrapolation of data from one group to another) is that developed countries may incur more mesothelioma cases because of an older age composition. However, this factor is probably offset by several potential sources of disease underestimation: a) a lack of data on the trade of asbestos-containing products could impose additional risk; b) our estimates cannot account for the national experiences of the majority of countries in the world with no information on asbestos use (USGS information on asbestos use may be less complete for the less-developed countries, especially for the earlier years); and c) underdiagnosis and underreporting of mesothelioma is also a major problem in developed countries. Therefore, our values should be viewed as conservative estimates.
It is plausible that the hidden burden is substantial in countries with high cumulative use of asbestos, including asbestos-producing countries such as Russia, Kazakhstan, China, and India. Underdiagnosis and/or underreporting may have occurred in these countries because of lack of awareness, knowledge, and resources. It is also possible that, even if mesothelioma cases are diagnosed domestically, frequency numbers are not actively disclosed to the international community because of the increasing number of countries adopting bans on asbestos use (Kazan-Allen 2005) on grounds of public health. Some countries with vested interest in maintaining the production and trade of asbestos may be poorly motivated to acknowledge ARDs. For example, Russia is known for not recognizing asbestosis in its territory (Walgate 2010).
The world nearly doubled cumulative use of asbestos from 65 million metric tons up until 1970, to 124 million metric tons since then. In particular, the group of 33 countries not reporting mesothelioma frequency quintupled asbestos use (Table 1). Individually, the number of countries exceeding the cumulative use of 3.0 million metric tons have increased from five in 1971 (United States, Russia, United Kingdom, Germany, and Japan) to eight: Russia (36.1 million metric tons), China (11.2), Kazakhstan (9.6), Japan (8.1), the United States (6.9), Brazil (5.3), Germany (5.2), India (4.5), and Thailand (3.6) (data not shown). Thus, even with the expected hygienic improvements to reduce exposure over time, and particularly since 1970 onward, these countries should anticipate the need to deal with a very high burden of mesothelioma in the immediate decades ahead.
Developed countries should share experience and technology to enable developing countries to promote accurate diagnosis, reporting, and management of ARDs (Takahashi 2008), including mesothelioma. Moreover, political will is essential to ensure that asbestos use ceases globally.


We estimated the 15-year cumulative frequency of mesothelioma during 1994–2008 in the 56 countries reporting mesothelioma to be 174,300. Using cumulative asbestos use to predict cumulative mesothelioma frequency at national levels, we predicted the 15-year cumulative frequency of mesothelioma during 1994–2008 in the 33 countries that do not report mesothelioma to be 38,900 (95% CI, 36,700–41,100). Thus, globally, for every four to five reported cases of mesothelioma, one case has been overlooked. These estimates support the need for countermeasures at national, regional, and international levels.

Article Notes

Supplemental Material is available online (doi:10.1289/ehp.1002845 via
We thank K. Cho (School of Medicine, Yale University) and M. Ohtaki (Department of Environmetrics and Biometrics, Research Institute for Radiation Biology and Medicine, Hiroshima University, Japan) for their valuable advice.
This work was supported in part by the Japan Society for the Promotion of Sciences (JSPS) Asia Africa (AA) Science Platform Program.


Antao VC, Pinheiro GA, Wassell JT. 2009. Asbestosis mortality in the USA: facts and predictions. Occup Environ Med 66:335-338
Centers for Disease Control and Prevention. 2009. Malignant mesothelioma mortality—United States, 1999–2005. MMWR Morb Mortal Wkly Rep 58:393-396
Driscoll T, Nelson DI, Steenland K, Leigh J, Concha-Barrientos M, Fingerhut Met al. 2005. The global burden of disease due to occupational carcinogens. Am J Ind Med 48:419-431
Duffield JS, Diehl PF, Lepgold J. 2003. Regional conflict management in Europe. Regional Conflict Management Lanham, MD Rowman and Littlefield Publishers 239-268.
Hodgson JT, McElvenny DM, Darnton AJ, Price MJ, Peto J. 2005. The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050. Br J Cancer 92:587-593
Kazan-Allen L. 2005. Asbestos and mesothelioma: worldwide trends. Lung Cancer 49((suppl 1)):S3-S8
Kjellstrom T, Smartt P. 2000. Increased mesothelioma incidence in New Zealand: the asbestos-cancer epidemic has started. N Z Med J 113:485-490
LaDou J. 2004. The asbestos cancer epidemic. Environ Health Perspect 112:285-290
Lee LJ, Chang YY, Wang JD. 2010. Impact of malignant mesothelioma in Taiwan: a 27-year review of population-based cancer registry data. Lung Cancer 68:16-19
Leigh J, Driscoll T. 2003. Malignant mesothelioma in Australia, 1945–2002. Int J Occup Environ Health 9:206-217
Lin RT, Takahashi K, Karjalainen A, Hoshuyama H, Wilson D, Kameda Tet al. 2007. Ecological association between asbestos-related diseases and historical asbestos consumption: an international analysis. Lancet 369:844-849
Marinaccio A, Binazzi A, Cauzillo G, Cavone D, Zotti RD, Ferrante Pet al. 2007. Analysis of latency time and its determinants in asbestos related malignant mesothelioma cases of the Italian register. Eur J Cancer 43:2722-2728
Murayama T, Takahashi K, Natori Y, Kurumatani N. 2006. Estimation of future mortality from pleural malignant mesothelioma in Japan based on an age-cohort model. Am J Ind Med 49:1-7
National Center for Biotechnology Information. 2010. PubMed Available: [accessed 22 February 2011].
Nishikawa K, Takahashi K, Karjalainen A, Wen CP, Furuya S, Hoshuyama Tet al. 2008. Recent mortality from pleural mesothelioma, historical patterns of asbestos use, and adoption of bans: a global assessment. Environ Health Perspect 116:1675-1680
Pelucchi C, Malvezzi M, La Vecchia C, Levi F, Decarli A, Negri E. 2004. The mesothelioma epidemic in Western Europe: an update. Br J Cancer 90:1022-1024
Peto J, Decarli A, La Vecchia C, Levi F, Negri E. 1999. The European mesothelioma epidemic. Br J Cancer 79:666-672
Rüegger M. 2008. Malignant Mesothelioma Recognized as Occupational Diseases in Switzerland [in German] Available: [accessed 15 July 2010].
Takahashi K. 2008. Asbestos-related diseases: time for technology sharing. Occup Med (London) 58:384-385
Takahashi K, Karjalainen A. 2003. A cross-country comparative overview of the asbestos situation in ten Asian countries. Int J Occup Environ Health 9:244-248
Tossavainen A. 1997. Asbestos, asbestosis, and cancer: the Helsinki criteria for diagnosis and attribution. Scand J Work Environ Health 23:311-316
Tossavainen A. 2004. Global use of asbestos and the incidence of mesothelioma. Int J Occup Environ Health 10:22-25
Tse LA, Yu IT, Goggins W, Clements M, Wang XR, Au JSet al. 2010. Are current or future mesothelioma epidemics in Hong Kong the tragic legacy of uncontrolled use of asbestos in the past? Environ Health Perspect 118:382-386
United Nations. 2010. Member States of the United Nations Available: [accessed 19 July 2010].
U.S. Census Bureau. 2010. International Data Base Available: [accessed 20 July 2010].
Virta RL. 2006. Worldwide Asbestos Supply and Consumption Trends from 1900 through 2003 Available: [accessed 11 July 2010].
Virta RL. 2009. World Asbestos Consumption from 2003 through 2007 Available: [accessed 11 July 2010].
Walgate R. 2010. European nations agree to improve environmental health. Lancet 375:969
WHO (World Health Organization). 1977. Manual of the International Statistical Classification of Diseases, Injuries, and Causes of Death 1 Geneva World Health Organization.
WHO (World Health Organization). 2006a. Elimination of Asbestos-Related Diseases Geneva World Health Organization Available: [accessed 20 July 2010].
WHO (World Health Organization). 2006b. International Statistical Classification of Diseases and Related Health Problems, 10th Revision; Version for 2007 Available: [accessed 22 February 2011].
WHO (World Health Organization). 2010a. World Health Organization Statistical Information System (WHOSIS): Download the Detailed Data Files of the WHO Mortality Database. Available: [accessed 17 July 2010].
WHO (World Health Organization). 2010b. About the WHO Mortality Data Available: [accessed 3 October 2010].

Information & Authors


Published In

Environmental Health Perspectives
Volume 119Issue 4April 2011
Pages: 514 - 518
PubMed: 21463977


Received: 9 August 2010
Accepted: 15 December 2010
Published online: 6 January 2011


  1. asbestos
  2. frequency
  3. mesothelioma
  4. mortality
  5. prediction



Eun-Kee Park
Department of Environmental Epidemiology, Institute of Industrial Ecological Sciences, University of Occupational and Environmental Health, Kitakyushu City, Japan
Ken Takahashi [email protected]
Department of Environmental Epidemiology, Institute of Industrial Ecological Sciences, University of Occupational and Environmental Health, Kitakyushu City, Japan
Tsutomu Hoshuyama
Department of Environmental Epidemiology, Institute of Industrial Ecological Sciences, University of Occupational and Environmental Health, Kitakyushu City, Japan
Tsun-Jen Cheng
Institute of Occupational Medicine and Industrial Hygiene, College of Public Health, National Taiwan University, Taipei, Taiwan
Vanya Delgermaa
Department of Environmental Epidemiology, Institute of Industrial Ecological Sciences, University of Occupational and Environmental Health, Kitakyushu City, Japan
Giang Vinh Le
Department of Environmental Epidemiology, Institute of Industrial Ecological Sciences, University of Occupational and Environmental Health, Kitakyushu City, Japan
Tom Sorahan
Institute of Occupational and Environmental Medicine, University of Birmingham, Edgbaston, Birmingham, United Kingdom


Address correspondence to K. Takahashi, Department of Environmental Epidemiology, Institute of Industrial Ecological Sciences, University of Occupational and Environmental Health, Iseigaoka 1-1, Yahatanishiku, Kitakyushu City, Fukuoka Prefecture 807-8555, Japan. Telephone: 81 93 691 7401. Fax: 81 93 601 7324. E-mail: [email protected]
K.T. received a research grant from the JSPS AA Science Platform. The remaining authors declare they have no actual or potential competing financial interests.

Metrics & Citations


About Article Metrics


Download citation

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click DOWNLOAD.

Cited by

  • Global, regional, and national burden of non-communicable diseases attributable to occupational asbestos exposure 1990–2019 and prediction to 2035: worsening or improving?, BMC Public Health, 10.1186/s12889-024-18099-4, 24, 1, (2024).
  • Malignant pleural disease, Breathe, 10.1183/20734735.0145-2023, 19, 4, (230145), (2024).
  • Asbestos Consumption and Malignant Mesothelioma Mortality Trends in the Major User Countries, Annals of Global Health, 10.5334/aogh.4012, 89, 1, (11), (2023).
  • Cullin 4B Ubiquitin Ligase Is Important for Cell Survival and Regulates TGF-β1 Expression in Pleural Mesothelioma, International Journal of Molecular Sciences, 10.3390/ijms241713410, 24, 17, (13410), (2023).
  • Mesothelioma Due to Workplace Exposure: A Comprehensive Bibliometric Analysis of Current Situation and Future Trends, International Journal of Environmental Research and Public Health, 10.3390/ijerph20042833, 20, 4, (2833), (2023).
  • Colorectal Cancer: 35 Cases in Asbestos-Exposed Workers, Healthcare, 10.3390/healthcare11233077, 11, 23, (3077), (2023).
  • Global, Regional, and National Burden of Mesothelioma 1990–2019: A Systematic Analysis of the Global Burden of Disease Study 2019, Annals of the American Thoracic Society, 10.1513/AnnalsATS.202209-802OC, 20, 7, (976-983), (2023).
  • Pleural mesothelioma risk in the construction industry: a case–control study in Italy, 2000–2018, BMJ Open, 10.1136/bmjopen-2023-073480, 13, 8, (e073480), (2023).
  • Psychosocial well-being among patients with malignant pleural mesothelioma, Palliative and Supportive Care, 10.1017/S1478951522001596, 22, 1, (57-61), (2023).
  • A Narrative Review—Management of Malignant Pleural Effusion Related to Malignant Pleural Mesothelioma, Heart, Lung and Circulation, 10.1016/j.hlc.2023.02.004, 32, 5, (587-595), (2023).
  • See more

View Options

View options


View PDF

Get Access

Restore your content access

Enter your email address to restore your content access:

Note: This functionality works only for purchases done as a guest. If you already have an account, log in to access the content to which you are entitled.







Copy the content Link

Share on social media